Key Highlights

  • DVA shares traded down 5.65% to $176.43, versus a prior close of $187.00.
  • No company-specific catalyst is evident in the available sources.
  • Q3 results are due after the close on Oct. 29.
  • Consensus EPS is about $3.57 on revenue near $3.5 billion.
  • 2026 adjusted EPS guidance has a midpoint of $14.65.

A Sharp Drop Against a Strong Sector

DaVita (NYSE:DVA) shares traded down 5.65% to $176.43 as the broader sector hit a record high. The healthcare sector was up roughly 1.8%, and Oppenheimer upgraded healthcare equipment and services to overweight. Volume was well above average.

No company-specific catalyst is evident, so the cause of the decline is unclear. Policy and reimbursement risks and rotation into other healthcare names are possible factors, though none are confirmed.

Q3 Earnings Date Confirmed for Oct. 29

DaVita announced after Monday's close that it will report Q3 results after the market closes on Oct. 29. Consensus calls for EPS of about $3.57 on revenue of about $3.5 billion. DaVita has beaten estimates in 5 of the last 7 quarters, including a Q2 EPS of $4.02 against a $3.88 consensus. TD Cowen recently named dialysis among its Q3 picks.

Guidance Remains the Anchor

Management reaffirmed 2026 guidance in Q2, with an adjusted operating income midpoint of $2.2 billion and an adjusted EPS midpoint of $14.65, bracketed by a low end of $14.10 and a high end of $15.20. It expects 2026 treatment volume growth near the top of a 25 to 50 basis point range, and a sequential rise in operating income from Q3 to Q4.

DaVita has a market capitalization of about $11.26 billion, a forward price-to-earnings ratio of 10.89 and a 52-week range of $101.00 to $247.49.

Treatment Volumes and Payer Mix Decide the Next Move

Investors will watch treatment volume trends, revenue per treatment, payer mix and any update on the hemodialysis technology rollout. With the drop unexplained, the Oct. 29 report is the next clear opportunity for the company to address the move.